adjust model post-earn marking-to-market
allscript model updat reflect chang inform disclos
part segment report revenu project softwar deliveri
client servic segment in-lin compani report allscript
longer provid file detail inform veradigm provid
revenu longer model break-out new pt impli
price-to-earnings multipl base case ep estim
compar compani grow top-line low singl digit
believ discount appropri given challeng oper environ
allscript face potenti implic custom base post
new pt impli price-to-earnings multipl appli
base case ep estim in-lin averag
compar softwar compani grow top-line lsd-msd ebitda
margin rang
inovalon updat model post-earn pt unchang
seek busi
compani cover morgan stanley research
result investor awar firm may
conflict interest could affect object
morgan stanley research investor consid
morgan stanley research singl factor make
invest decis
analyst certif import disclosur
refer disclosur section locat end
lt growth depend new strateg initi partnership
dcf-deriv pt wacc medium-term growth rate termin
market leader global
ehr market account share
us market market alreadi
penetr greeneld opportun
hospit continu shift
spend area outsid core
popul key manag
deliv long-term top-line growth
strateg growth initi
consum employ medicaid
provid upsid option requir
increment invest outsid
cut initi expand
oper margin near-to-mid term
view descript risk reward theme
thomson reuter morgan stanley research morgan stanley institut equiti divis probabl
bull base bear case scenario play estim impli volatil data option market
may gure approxim risk-neutr probabl stock reach beyond scenario price
either three-month one-year time view explan option probabl methodolog
price-to-earnings multipl appli bull
price-to-earnings multipl appli bull
case ep estim
case ep estim revenu
re-acceler high singl digit due
faster-than-expect uptak revenu
offer newer offer ebitda
margin expand beyond rang
multipl in-lin compar
softwar compani grow top-line
hsd ebitda margin
price-to-earnings multipl appli base
price-to-earnings multipl appli base
case ep estim
case ep estim revenu
grow low-mid single-digit
ebitda margin rang
impli multipl modestli
averag compar softwar compani
grow top-line lsd-msd
ebitda margin rang
price-to-earnings multipl appli bear case
price-to-earnings multipl appli bear case
ep estim
ep estim revenu
growth deceler low-single-digit
ebitda margin rang
multipl in-lin compar
softwar compani grow top-line
lsd ebitda margin mid-high
view explan region hierarchi
research highest favor quintil
faster expect ramp va contract
revenu acceler non-cor product
popul health itwork
expans hospit hcit budget
revenu deceler ebit declin
ration low-margin contract
lack traction non-cor product
implement delay va contract
fund exposur held mspb inform may
inconsist may reect broader market
exposur sector total net exposur
across sector long exposur short exposur
margin improv expens top-line growth
dcf-base price target use wacc mid-term growth termin growth
allscript diversi hcit vendor
client primarili provid market
physician ofc hospit given
underli fundament industri
see challeng achiev sustain
growth market
could improv ebitda margin
expens top-line growth opportun
pressur book margin
view descript risk reward theme
impli bull case ep
top-line growth rate
top-line growth rate mid-term
termin growth rate also
assum ebitda margin expand
compani busi
transform initi success
cost cut achiev beyond near-term
impli base case ep
top-line growth rate
top-line growth rate mid-term
termin growth rate also
assum ebitda margin expand
high-teen in-lin current compani
target part busi
transform cost-cut initi
impli base case ep
top-line growth rate
top-line growth rate mid-term
termin growth rate also
assum ebitda margin remain
low-mid teen assum busi
transform cost-cut initi
success
quarterli result focu book
china india
view explan region hierarchi
research highest favor quintil
re-acceler provid budget spend
expans wallet share among core
greater expect contribut
increas deal synergi oper
contract provid budget
deceler veradigm revenu growth
fund exposur held mspb inform may
inconsist may reect broader market
exposur sector total net exposur
across sector long exposur short exposur
custom renew visibl revenu acv trend support pt
multiples-bas price target assum multipl ebitda in-lin
averag ev/ebitda multipl softwar compani grow top-line
hsd-ldd ebitda margin rang
inovalon provid cloud-bas
healthcar manag care organ
provid pharmaci life scienc
expect top-line organ growth
hsd-ldd rang contract
renew rate rang
revenu come subscript
increas visibl futur revenu
expect platform invest
oper efcienc continu drive
ebitda growth margin expans
slightli off-set invest sale
view descript risk reward theme
bull case ebitda
ev/ebitda multipl appli
ev/ebitda multipl appli
bull case ebitda estim
bull case ebitda estim
million revenu acceler mid-teen
ebitda margin improv high-
base case ebitda
ev/ebitda multipl appli
ev/ebitda multipl appli
base case ebitda estim
base case ebitda estim
million revenu growth remain hsd-
ldd ebitda margin remain mid-
bear case ebitda
ev/ebitda multipl appli
ev/ebitda multipl appli
bear case ebitda estim
bear case ebitda estim
million revenu growth declin mid-
singl digit ebitda margin remain
rang
acceler acv
view explan region hierarchi
research highest favor quintil
fund exposur held mspb inform may
inconsist may reect broader market
exposur sector total net exposur
across sector long exposur short exposur
